亘喜生物(GRCL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GRCL 亘喜生物

停牌 04-19 10:00:36 EDT

10.25

+0.00

0.00%

最高10.25	最低10.25	成交量0.00
今开10.25	昨收10.25	日振幅0.00%
总市值9.91亿	流通市值3.41亿	总股本9,671万
成交额6,573万	换手率0.00%	流通股本3,328万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GRCL","market":"US","secType":"STK","nameCN":"亘喜生物","latestPrice":10.25,"timestamp":1708549200000,"preClose":10.25,"halted":3,"volume":0,"delay":0,"floatShares":33278469,"shares":96712353,"eps":-0.950223,"marketStatus":"停牌","marketStatusCode":2,"change":0,"latestTime":"04-19 10:00:36 EDT","open":10.25,"high":10.25,"low":10.25,"amount":65729813.680143,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.950223,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1713556800000},"adr":0,"listingDate":1610082000000,"adjPreClose":10.25,"adrRate":5,"volumeRatio":0},"requestUrl":"/m/hq/s/GRCL","defaultTab":"news","newsList":[{"id":"2426649266","title":"130亿的并购，投资人俩月赚4倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2426649266","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2426649266?lang=zh_cn&edition=full","pubTime":"2024-04-10 21:48","pubTimestamp":1712756923,"startTime":"0","endTime":"0","summary":"B轮投资人在短短两个月后，就已经锁定退出，而且预计将获得超过4倍的收益，这无疑也是近年来的最快退出记录。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/7abf7205-b2eb-4790-903d-b3325384124d.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/7abf7205-b2eb-4790-903d-b3325384124d.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3712431","is_publish_highlight":false,"gpt_icon":0},{"id":"2425954227","title":"俩月赚4倍，最快退出诞生了","url":"https://stock-news.laohu8.com/highlight/detail?id=2425954227","media":"投中网","top":-1,"share":"https://www.laohu8.com/m/news/2425954227?lang=zh_cn&edition=full","pubTime":"2024-04-08 16:31","pubTimestamp":1712565084,"startTime":"0","endTime":"0","summary":"130亿交易落地，这次轮到20多家投资机构庆祝了。前几日，创新药巨头Genmab发布公告称，将以18亿美元（约130亿人民币）全现金形式，收购普方生物（ProfoundBio）。这是自去年底以来，国内第四家被收购的ADC公司。也刷新了此前亘喜生物以12亿美元的价格卖给阿斯利康的纪录。根据公告信息显示，这笔收购将使 Genmab 获得三项处...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/O3TOXYP29r8dVbCIpxIf8KLpdV0oFc-KxEzageUFAE-zMAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/O3TOXYP29r8dVbCIpxIf8KLpdV0oFc-KxEzageUFAE-zMAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240408A05ZKY00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240408A05ZKY00","is_publish_highlight":false,"gpt_icon":0},{"id":"2425669170","title":"一家B轮公司，卖了130亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2425669170","media":"蓝鲸财经","top":-1,"share":"https://www.laohu8.com/m/news/2425669170?lang=zh_cn&edition=full","pubTime":"2024-04-07 16:45","pubTimestamp":1712479541,"startTime":"0","endTime":"0","summary":"一笔极具标杆性的并购诞生了。近日，丹麦药企Genmab以18亿美元的高价，并购普方生物。官网显示，普方生物是一家成立于2019年的临床阶段生物技术公司，由赵柏腾、韩泰熙、尚晓三位博士创立，开发了一系列针对多种肿瘤靶点的ADC药物产品管线。值得一提的是，三人此前均有在生物技术公司Seagen的工作经历，要知道作为ADC先驱，Seagen曾被辉瑞以430亿美元的“天价”收购而引人瞩目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/230090","is_publish_highlight":false,"gpt_icon":0},{"id":"2413734046","title":"亘喜生物并入阿斯利康 将从纳斯达克退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2413734046","media":"北京商报","top":-1,"share":"https://www.laohu8.com/m/news/2413734046?lang=zh_cn&edition=full","pubTime":"2024-02-23 17:09","pubTimestamp":1708679372,"startTime":"0","endTime":"0","summary":"2月23日，亘喜生物科技集团宣布正式完成了此前公告的与阿斯利康集团的合并协议。合并完成后，亘喜生物不再是一家上市公司，而成为母公司的全资子公司。公司已要求纳斯达克向美国证券交易委员会（SEC）提交25表格，通知SEC本公司将从纳斯达克退市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202402232993093120.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202402232993093120.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2413330777","title":"亘喜生物并入阿斯利康集团，将从纳斯达克退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2413330777","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2413330777?lang=zh_cn&edition=full","pubTime":"2024-02-23 15:54","pubTimestamp":1708674892,"startTime":"0","endTime":"0","summary":"2月22日，亘喜生物科技集团宣布正式完成了此前公告的与阿斯利康集团的合并协议。合并子公司是一家根据开曼群岛法律注册成立的豁免有限责任公司，也是母公司的全资子公司。此次合并中，合并子公司与亘喜生物进行合并，亘喜生物作为存续公司成为母公司的全资子公司。公司已要求纳斯达克向美国证券交易委员会提交25表格，通知SEC本公司将从纳斯达克退市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402231554527a46053b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402231554527a46053b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413215076","title":"亘喜生物宣布正式并入阿斯利康集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2413215076","media":"GlobeNewswire","top":-1,"share":"https://www.laohu8.com/m/news/2413215076?lang=zh_cn&edition=full","pubTime":"2024-02-22 13:45","pubTimestamp":1708580700,"startTime":"0","endTime":"0","summary":"今日，公司宣布正式完成了此前公告的与阿斯利康集团的合并协议。合并完成后，亘喜生物不再是一家上市公司，而成为母公司的全资子公司。在提交25表格的10天后，退市申请将正式生效。任何本声明中的前瞻性声明仅反应当前的预期，亘喜生物并无责任公开更新或回顾任一前瞻性声明，无论是基于新信息、未来事件或是其他原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/02/22/2833709/0/zh-hans/%E4%BA%98%E5%96%9C%E7%94%9F%E7%89%A9%E5%AE%A3%E5%B8%83%E6%AD%A3%E5%BC%8F%E5%B9%B6%E5%85%A5%E9%98%BF%E6%96%AF%E5%88%A9%E5%BA%B7%E9%9B%86%E5%9B%A2.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2412017997","title":"亘喜生物宣布公司股东正式投票表决通过了与阿斯利康的并购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2412017997","media":"GlobeNewswire","top":-1,"share":"https://www.laohu8.com/m/news/2412017997?lang=zh_cn&edition=full","pubTime":"2024-02-20 12:45","pubTimestamp":1708404300,"startTime":"0","endTime":"0","summary":"公司宣布在2024年2月19日召开的特别股东大会上，经公司股东投票表决，通过了一项批准并授权公司正式执行、交付并履行此前于2023年12月23日宣布的拟议并购协议的提案。每位股东的每股普通股对应一票表决权。这些股份约占2024年1月8日开曼群岛收市时公司普通股总流通股所代表的投票权总数的94.8%。此次EGM，经股东投票表决，约99.9%的股东投票赞成该并购协议、合并计划以及交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/02/20/2831732/0/zh-hans/%E4%BA%98%E5%96%9C%E7%94%9F%E7%89%A9%E5%AE%A3%E5%B8%83%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%AD%A3%E5%BC%8F%E6%8A%95%E7%A5%A8%E8%A1%A8%E5%86%B3%E9%80%9A%E8%BF%87%E4%BA%86%E4%B8%8E%E9%98%BF%E6%96%AF%E5%88%A9%E5%BA%B7%E7%9A%84%E5%B9%B6%E8%B4%AD%E5%8D%8F%E8%AE%AE.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2407253852","title":"亘喜生物宣布FasTCAR-T GC012F早线治疗多发性骨髓瘤的1期新药临床试验（IND）申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2407253852","media":"GlobeNewswire","top":-1,"share":"https://www.laohu8.com/m/news/2407253852?lang=zh_cn&edition=full","pubTime":"2024-01-29 12:00","pubTimestamp":1706500800,"startTime":"0","endTime":"0","summary":"此次获批，是美国FDA授予GC012F的第三个IND批件。目前，公司正在开展FasTCAR-T GC012F的多项临床研究，适应症覆盖多种血液肿瘤和自身免疫性疾病。近日，美国FDA再次批准了GC012F早线治疗多发性骨髓瘤的IND申请。核心产品BCMA/CD19双靶点FasTCAR-T GC012F目前正处于一系列临床试验中，以探索其针对多发性骨髓瘤、B细胞非霍奇金淋巴瘤以及系统性红斑狼疮的治疗效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/01/29/2818739/0/zh-hans/%E4%BA%98%E5%96%9C%E7%94%9F%E7%89%A9%E5%AE%A3%E5%B8%83FasTCAR-T-GC012F%E6%97%A9%E7%BA%BF%E6%B2%BB%E7%96%97%E5%A4%9A%E5%8F%91%E6%80%A7%E9%AA%A8%E9%AB%93%E7%98%A4%E7%9A%841%E6%9C%9F%E6%96%B0%E8%8D%AF%E4%B8%B4%E5%BA%8A%E8%AF%95%E9%AA%8C-IND-%E7%94%B3%E8%AF%B7%E8%8E%B7%E7%BE%8E%E5%9B%BDFDA%E6%89%B9%E5%87%86.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2400744357","title":"AZ出手收购亘喜生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2400744357","media":"证券市场周刊","top":-1,"share":"https://www.laohu8.com/m/news/2400744357?lang=zh_cn&edition=full","pubTime":"2024-01-04 17:17","pubTimestamp":1704359837,"startTime":"0","endTime":"0","summary":"12月26日，AZ宣布收购亘喜生物，对价包括约10亿美元现金+或有价值权益约2亿美元，CVR条件包括核心管线GC-012F在2028年底获得FDA的加速批准或在2029年底前获得完全批准，交易总金额高达12亘喜的FasTCAR平台以及核心这款BCMA/CD19 CAR-T疗法GC-012F，究竟价值几何，多少在市场上还存在一定的争议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401041725388793eae7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401041725388793eae7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2400318418","title":"中国Biotech卖身第一案：一场非典型并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2400318418","media":"深蓝观","top":-1,"share":"https://www.laohu8.com/m/news/2400318418?lang=zh_cn&edition=full","pubTime":"2024-01-02 15:32","pubTimestamp":1704180720,"startTime":"0","endTime":"0","summary":"中国Biotech的优势在于人才成本","market":"hk","thumbnail":"https://img.huxiucdn.com/article/cover/202401/02/125201205828.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202401/02/125201205828.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.huxiu.com/article/2485589.html","is_publish_highlight":false,"gpt_icon":0},{"id":"1185510638","title":"ETF追踪 | 生物科技行业2024：交易激增、创新迎来曙光","url":"https://stock-news.laohu8.com/highlight/detail?id=1185510638","media":"ETF小帮手","top":-1,"share":"https://www.laohu8.com/m/news/1185510638?lang=zh_cn&edition=full","pubTime":"2023-12-31 20:11","pubTimestamp":1704024683,"startTime":"0","endTime":"0","summary":"生物科技行业正在迎来复苏，摆脱了一段时间的低迷。展望2024年，分析师们预计更有利的利率环境、交易活动的增加，以及在癌症和免疫学等关键领域的创新将为生物技术公司带来更为光明的前景。自10月底以来，生物科技行业的指数已经上涨了29%。这两个行业在截至2023年12月28日的12个月内共进行了超2220亿美元的并购交易。该 ETF 目前拥有约 275 只生物科技股票。ETF 通常持有 40 至 60 只股票。方舟基因革命ETF于2014年开始交易。","market":"hk","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2394574308","title":"阿斯利康高溢价收购亘喜生物，CAR-T疗法彻底火了","url":"https://stock-news.laohu8.com/highlight/detail?id=2394574308","media":"钛媒体","top":-1,"share":"https://www.laohu8.com/m/news/2394574308?lang=zh_cn&edition=full","pubTime":"2023-12-28 22:20","pubTimestamp":1703773245,"startTime":"0","endTime":"0","summary":"来源于视觉中国先是“系统性红斑狼疮”的“新解药”，后是巨额的收购案，让CAR-T细胞疗法彻底火了。而亘喜生物在CAR-T疗法上表现出来的优势主要得益于其开创性的FastCAR平台。而亘喜生物的FasTCAR次日生产技术平台，不但能显著缩短生产时间，还能强化T细胞健康状态，进而有望提高自体CAR-T疗法的有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122822205481841bd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122822205481841bd0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2394211795","title":"创始人80亿卖公司，VC全体赚钱退出","url":"https://stock-news.laohu8.com/highlight/detail?id=2394211795","media":"投中网","top":-1,"share":"https://www.laohu8.com/m/news/2394211795?lang=zh_cn&edition=full","pubTime":"2023-12-28 14:12","pubTimestamp":1703743978,"startTime":"0","endTime":"0","summary":"85亿，第一个中国Biotech上市公司卖身交易诞生了。该交易预计将于2024年第一季度完成，交易完成后，亘喜生物将从纳斯达克交易所退市，成为一家私有化控股公司。截至2023年9月30日，亘喜生物资产负债表上的现金和有价证券总额为2.34亿美元。这场2023年细胞治疗公司并购金额最大交易，让亘喜生物背后的一级市场投资机构以及二级市场定增机构全都得以获利退出。具体来看，本次收购价格最高每份ADS 11.50美元，远高于一级投资者的买入价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231228141308877bc5f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231228141308877bc5f2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2394476472","title":"首家中国创新药企被跨国药企收购，一条新的退出路径被走通","url":"https://stock-news.laohu8.com/highlight/detail?id=2394476472","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2394476472?lang=zh_cn&edition=full","pubTime":"2023-12-28 11:08","pubTimestamp":1703732909,"startTime":"0","endTime":"0","summary":"该交易预计将于2024年第一季度完成。一条新的退出路径对于这“历史首单”，业内的看法普遍比较积极。有观点认为，CAR-T疗法成本高昂，而亘喜生物的产品又均处于早期，难以完成国内外的临床试验，此次被收购，解决了潜在的现金危机。此次交易也被认为是对中国创新药行业实力的证明，使业界对未来跨国药企收购中国Biotech潮流产生遐想。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122811101181824adf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122811101181824adf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2394768227","title":"12亿美元“卖身”阿斯利康，亘喜生物有何魔力？","url":"https://stock-news.laohu8.com/highlight/detail?id=2394768227","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2394768227?lang=zh_cn&edition=full","pubTime":"2023-12-28 09:05","pubTimestamp":1703725510,"startTime":"0","endTime":"0","summary":"12月26日，生物医药行业又迎来新消息，亘喜生物公告称，公司已与阿斯利康对其的收购提案达成最终协议。与此同时，截至2023年9月30日，亘喜生物资产负债表上的现金和有价证券总额为2.34亿美元。值得一提的，本次阿斯利康拟对亘喜生物的收购为溢价收购，此举也拉升了亘喜生物股价。如果这笔首付款以及潜在的或有价值付款达成的话，合计交易价值约为12亿美元，较之亘喜生物在2023年12月22日的收盘价溢价86%，比60天的VWAP溢价192%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231228090513877adf9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231228090513877adf9c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2394739989","title":"阿斯利康溢价192%收购亘喜生物，Biotech曙光来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2394739989","media":"蓝鲸财经","top":-1,"share":"https://www.laohu8.com/m/news/2394739989?lang=zh_cn&edition=full","pubTime":"2023-12-27 22:41","pubTimestamp":1703688086,"startTime":"0","endTime":"0","summary":"最终协议条款显示，此次收购合计交易价值最高约为12亿美元，与亘喜生物12月22日的收盘价相比溢价86%，比60天成交量加权平均价格溢价192%。阿斯利康本次收购亘喜生物也在医药圈引发热议，不少业内人士认为，阿斯利康收购亘喜生物在一定程度上也证明了中国创新药行业的实力。此外，亘喜生物的差异化生产工艺，能够降低生产成本。亘喜生物被阿斯利康收购还是属于个案，但是对于整体Biotech投融资上还是会起到一定的提振作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122722432287799ee4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122722432287799ee4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2394979782","title":"首例！中国创新药公司被跨国药企收购 阿斯利康为何要买亘喜生物？","url":"https://stock-news.laohu8.com/highlight/detail?id=2394979782","media":"红星资本局","top":-1,"share":"https://www.laohu8.com/m/news/2394979782?lang=zh_cn&edition=full","pubTime":"2023-12-27 19:02","pubTimestamp":1703674938,"startTime":"0","endTime":"0","summary":"红星资本局12月27日消息，阿斯利康中国与亘喜生物（GRCL.US）昨日双双宣布达成收购协议。受将被阿斯利康收购消息影响，中概股亘喜生物周二大涨60.26%，报9.92美元/股，总市值9.52亿美元。收购协议显示，首付款约为10亿美元，若该笔首付款以及潜在的或有价值付款达成，合计交易价值约为12亿美元。值得注意的是，这也是跨国药企收购中国创新药公司的史上首例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202312272945348381.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2394202682","title":"AZ溢价收购亘喜生物后，国内Biotech或即将开启“卖身潮”","url":"https://stock-news.laohu8.com/highlight/detail?id=2394202682","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2394202682?lang=zh_cn&edition=full","pubTime":"2023-12-27 15:40","pubTimestamp":1703662810,"startTime":"0","endTime":"0","summary":"阿斯利康的溢价收购直接拉升了亘喜生物当日的股价，最终其收涨高达60.26%。对于这笔交易，阿斯利康在26日表示，“12亿美元收购亘喜生物，旨在补充阿斯利康在细胞治疗方面的现有能力和先前的投资规模。”国内Biotech即将开启“卖身潮”?作为首家在二级市场被MNC收购的中国biotech公司。亘喜生物最终的交易对价最高将达到每份ADS 11.50美元。这一价格将让亘喜生物背后的一级市场投资机构以及二级市场定增机构全都得以获利退出。","market":"us","thumbnail":"https://static.tigerbbs.com/a3f00ceb9616da9533f38a065954d799","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a3f00ceb9616da9533f38a065954d799"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1045812.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2394127755","title":"阿斯利康与亘喜生物达成全资收购协议，加快细胞疗法进入海外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2394127755","media":"IPO早知道","top":-1,"share":"https://www.laohu8.com/m/news/2394127755?lang=zh_cn&edition=full","pubTime":"2023-12-27 10:39","pubTimestamp":1703644768,"startTime":"0","endTime":"0","summary":"\"拟议收购将为阿斯利康细胞疗法管线增添GC012F CAR-T细胞疗法。\"      本文为IPO早知道原创      作者｜罗宾      据IPO早知道消息，12月26日，亘喜生物（GRCL.U....","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OUk41QfnTVNkorrF43eqXHYb8nbFCEeP21XeUnMcSVcB8AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OUk41QfnTVNkorrF43eqXHYb8nbFCEeP21XeUnMcSVcB8AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20231227A02PLM00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20231227A02PLM00","is_publish_highlight":false,"gpt_icon":0},{"id":"2394275158","title":"亘喜生物美股股价涨60% 阿斯利康12亿美元收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2394275158","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2394275158?lang=zh_cn&edition=full","pubTime":"2023-12-27 08:45","pubTimestamp":1703637900,"startTime":"0","endTime":"0","summary":"中国经济网北京12月27日讯 亘喜生物(NASDAQ:GRCL)美股周二收报9.92美元，涨幅60.26%，总市值9.52亿美元。据每日经济新闻报道，12月26日，阿斯利康宣布，已就对亘喜生物科技集团（简称亘喜生物）收购提案签署最终协议，进一步深化阿斯利康在细胞疗法领域布局。亘喜生物是一家面向全球、处于临床阶段的生物制药企业，致力于开发治疗肿瘤及自身免疫性疾病的创新性细胞疗法。此次拟议收购将为阿斯利康不断扩充的细胞疗法管线增添GC012F CAR-T细胞疗法。阿斯利康表示，此项交易合计价值约为12亿美元，亘喜生物将作为阿斯利康全资子公司继续在中国及美国运营。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122708514887773683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122708514887773683&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gracellbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0.026},{"period":"6month","weight":2.559},{"period":"1year","weight":4.2296},{"period":"ytd","weight":0.0209}],"compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0314},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.186},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.0509}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"亘喜生物科技公司是一家获豁免的有限责任公司，于2018年5月22日在开曼群岛注册成立,是一家致力于发现和开发突破性细胞疗法的全球临床阶段生物制药公司。利用其开创性FasTCAR和TruUCAR技术平台，亘喜生物正在开发多项自体和同种异体的丰富临床阶段癌症治疗产品管线。这些产品有望攻克传统CAR-T疗法持续存在的重大行业挑战，包括生产时间长、产品细胞质量欠佳、治疗成本高和对实体瘤缺乏有效治疗等。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.15318},{"month":2,"riseRate":0.5,"avgChangeRate":-0.016645},{"month":3,"riseRate":0,"avgChangeRate":-0.222234},{"month":4,"riseRate":0,"avgChangeRate":-0.102647},{"month":5,"riseRate":1,"avgChangeRate":0.424463},{"month":6,"riseRate":0.666667,"avgChangeRate":0.308486},{"month":7,"riseRate":0,"avgChangeRate":-0.137509},{"month":8,"riseRate":0,"avgChangeRate":-0.193275},{"month":9,"riseRate":0.666667,"avgChangeRate":0.163579},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.023734},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063859},{"month":12,"riseRate":0.333333,"avgChangeRate":0.183219}],"exchange":"NASDAQ","name":"亘喜生物","nameEN":"Gracell Biotechnologies Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亘喜生物(GRCL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亘喜生物(GRCL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亘喜生物,GRCL,亘喜生物股票,亘喜生物股票老虎,亘喜生物股票老虎国际,亘喜生物行情,亘喜生物股票行情,亘喜生物股价,亘喜生物股市,亘喜生物股票价格,亘喜生物股票交易,亘喜生物股票购买,亘喜生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亘喜生物(GRCL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亘喜生物(GRCL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}